Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: Results of a prospective, randomized, double-blind clinical trial

Robert E. Condon, Alonzo P. Walker, Kenneth R. Sirinek, Patrick W. White, Timothy C. Fabian, Ronald L. Nichols, Samuel E. Wilson

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Abstract

The efficacy of meropenem was compared to that of the combination of tobramycin plus clindamycin (T/C) in a multiinstitutional clinical trial of treatment for patients suffering intraabdominal infection. Among the 177 patients enrolled and randomized, 127 were clinically evaluable and 86 were microbiologically evaluable. Analysis of data on an intent-to-treat basis for all randomized patientsand on the basis of a successful outcome (absence of any infection) for clinically evaluable patientsfailed to detect any difference in efficacy between the two treatments. Infection was cleared in 92% of meropenem- and 89% of T/C-treated clinically evaluable patients. Eradication of pathogens also wassimilar in the two treatment groups. Overall, adverse drug experiences were comparable between the two treatment groups, with the exception of an increase in serum creatinine level (which occurred more frequently in patients receiving T/C). Meropenem appears to be efficacious for the treatment of intraabdominal infections.

Original languageEnglish (US)
Pages (from-to)544-550
Number of pages7
JournalClinical Infectious Diseases
Volume21
Issue number3
DOIs
StatePublished - Sep 1995

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: Results of a prospective, randomized, double-blind clinical trial'. Together they form a unique fingerprint.

Cite this